옵션 체인은 다양한 행사가격과 만기일에 대한 Capricor Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Capricor Therapeutics에 대한 시장 심리를 평가합니다..

Capricor Therapeutics (NASDAQ:CAPR) 주식, 옵션 체인

Capricor Therapeutics

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Equities

News

Markets

BABA

CAPR

NVDA

TSLA

화요일에 주요 미국 지수들이 상승했다. 다우존스 산업평균지수가 0.2% 상승하여 42,208.22에, S&amp;P 500이 0.25% 상승하여 5,732.93에, 나스닥이 0.6% 상승하여 18,074.52에 장을 마쳤다.

화요일 주목받은 주식 5종목: 엔비디아, 알리바바, 카프리코, TSMC 그리고 테슬라

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics Inc

CAPRAL LTD by Capral Ltd.

CAPRI HOLDINGS ORD

Capri Holdings Ltd

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

CAPRICORN ENERGY PLC by CAPRICORN ENERGY PLC

Capricorn Energy PLC ADR

CAPRICORN METALS LTD by CAPRICORN METALS LTD.

Capricorn Metals Ltd

Deep-pocketed investors have adopted a bearish approach towards Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAPR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Capricor Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 27% leaning bullish and 54% bearish. Among these notable options, 3 are puts, totaling $146,410, and 8 are calls, amounting to $463,700.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $30.0 for Capricor Therapeutics over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Capricor Therapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Capricor Therapeutics's whale activity within a strike price range from $5.0 to $30.0 in the last 30 days. 
<h3>Capricor Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729714523_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$16.5</td>
<td>$15.7</td>
<td>$15.9</td>
<td>$5.00</td>
<td>$111.3K</td>
<td style="text-align: right;">803</td>
<td style="text-align: right;">70</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$16.6</td>
<td>$16.0</td>
<td>$16.3</td>
<td>$5.00</td>
<td>$81.5K</td>
<td style="text-align: right;">803</td>
<td style="text-align: right;">120</td>
</tr>
<tr>
<td>CAPR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$15.6</td>
<td>$14.2</td>
<td>$15.22</td>
<td>$30.00</td>
<td>$76.1K</td>
<td style="text-align: right;">58</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$25.00</td>
<td>$72.1K</td>
<td style="text-align: right;">216</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$25.00</td>
<td>$55.3K</td>
<td style="text-align: right;">216</td>
<td style="text-align: right;">158</td>
</tr>
</tbody>
</table>

<h3>About Capricor Therapeutics</h3>
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
After a thorough review of the options trading surrounding Capricor Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Capricor Therapeutics's Current Market Status</h3>
<ul>
<li>With a volume of 1,798,587, the price of CAPR is up 5.46% at $21.24. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 20 days.</li>
</ul>
<h3>Professional Analyst Ratings for Capricor Therapeutics</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $44.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Piper Sandler downgraded its rating to Overweight, setting a price target of $35. 
&#x2A; An analyst from HC Wainwright &amp; Co. has decided to maintain their Buy rating on Capricor Therapeutics, which currently sits at a price target of $77. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $40. 
&#x2A; An analyst from Maxim Group has decided to maintain their Buy rating on Capricor Therapeutics, which currently sits at a price target of $25. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Capricor Therapeutics, targeting a price of $43. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Capricor Therapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Capricor Therapeutics Options Trading: A Deep Dive into Market Sentiment

WIIM

Capricor Therapeutics shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a price target of $35.

Piper Sandler analyst Edward Tenthoff initiates coverage on Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Overweight rating and announces Price Target of $35.

Price Target

Initiation

Analyst Ratings

Piper Sandler Initiates Coverage On Capricor Therapeutics with Overweight Rating, Announces Price Target of $35

Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares are trading lower by 6.05% to $19.27 during Thursday&#8217;s session. The company earlier commenced its <a href="https://www.benzinga.com/pressreleases/24/10/g41375519/capricor-therapeutics-announces-pricing-of-approximately-75-million-public-offering-of-common-stoc">public offering of common stock</a>.
What To Know: The company announced the pricing of its public offering of 4.41 million shares at $17.00 per share. The company granted underwriters a 30-day option to purchase an additional 661,800 shares. 
The offering, expected to close on October 18, will raise approximately $75 million before expenses and commissions. 
Piper Sandler &amp; Co. and Oppenheimer &amp; Co. Inc. are managing the offering. Capricor says the company plans to use the funds for product development, manufacturing, working capital, and general corporate purposes.
Stock Of The Day: <a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41383732/stock-of-the-day-taiwan-semiconductor-breaks-out-as-buyers-push-prices-higher">Taiwan Semiconductor Breaks Out As Buyers Push Prices Higher</a>
<h2 class="wp-block-heading">Should I Sell My CAPR Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Capricor Therapeutics stock currently has an RSI of 61.26, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>

Why Capricor Therapeutics (CAPR) Shares Are Trading Lower

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.
Shares of CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41369567/csx-stock-falls-after-worse-than-expected-q3-results-details">third-quarter earnings below analyst estimates.</a>
CSX reported quarterly GAAP earnings of 46 cents per share, which missed the consensus estimate of 48 cents per share. Quarterly revenue came in at $3.62 billion, also missing the consensus estimate of $3.676 billion. The company said its total volume of 1.59 million units for the quarter was 3% higher as compared to the third quarter of 2023.
CSX shares dipped 5.4% to $33.55 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares dipped 16.2% to $3.37 in pre-market trading after surging 122% on Wednesday.</li>
<li>Lucid Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) declined 14.6% to $2.80 in pre-market trading after the company announced a public offering of common stock, along with a corresponding investment by an affiliate of the Public Investment Fund.</li>
<li>Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares fell 13.2% to $0.6350 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares fell 10.6% to $18.33 in pre-market trading. The company commenced its public offering of common stock.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares fell 8.8% to $1.64 in pre-market trading after the company provided updates on its INTERCEPT red blood cell programs in the US and Europe.</li>
<li>KE Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NASDAQ">BEKE</a>) shares declined 7.7% to $20.23 in pre-market trading after gaining around 5% on Wednesday.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) shares fell 6.4% to $15.41 in pre-market trading.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) shares fell 5.4% to $4.22 in pre-market trading following downbeat third-quarter results. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Movers

Trading Ideas

BEKE

CERS

LCID

LILM

MNSO

PRQR

CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Capricor Therapeutics shares are trading lower. The company commenced its public offering of common stock.

The gross proceeds from the offering are expected to be approximately&nbsp;$75 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Capricor and assuming no exercise of the underwriters&#39; option.

Offerings

Capricor Therapeutics Prices Public Offering Of 4.412M Shares Of Common Stock At $17.00 Per Share

<h3>Gainers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock increased by 189.2% to $0.94 during Wednesday's after-market session. The company's market cap stands at $6.1 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 21.72% to $0.68. The company's market cap stands at $14.5 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares moved upwards by 12.23% to $1.0. The market value of their outstanding shares is at $5.7 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) shares moved upwards by 5.9% to $6.99. The market value of their outstanding shares is at $130.3 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) stock rose 5.17% to $18.5. The company's market cap stands at $117.3 million. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) shares moved upwards by 5.08% to $1.24. The company's market cap stands at $88.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares fell 14.8% to $0.54 during Wednesday's after-market session. The company's market cap stands at $20.4 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 12.74% to $7.33. The market value of their outstanding shares is at $106.4 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock decreased by 11.07% to $18.24. The company's market cap stands at $644.5 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 10.98% to $5.76. The company's market cap stands at $5.9 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares declined by 10.4% to $0.56. The company's market cap stands at $11.7 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares declined by 9.45% to $1.63. The market value of their outstanding shares is at $302.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASMB

ATNF

BDRX

CHRO

CTCX

HCWB

KLTO

MTEM

NVCT

OVID

12 Health Care Stocks Moving In Wednesday's After-Market Session

Capricor Therapeutics Commences Public Offering Of Common Stock; Terms Not Disclosed

Capricor Therapeutics May Offer And Sell Up To $150M In Common Stock, Preferred Stock, Debt Securities, Warrants, And Units In One Or More Offerings

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$116.00</td>
<td>$116.9K</td>
<td>3.7K</td>
<td>3.7K</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$100.00</td>
<td>$66.3K</td>
<td>2.4K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MOH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$330.00</td>
<td>$156.4K</td>
<td>55</td>
<td>720</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.00</td>
<td>$77.0K</td>
<td>3</td>
<td>550</td>
</tr>
<tr>
<td>EWTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$35.00</td>
<td>$30.0K</td>
<td>16</td>
<td>300</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/25/24</td>
<td>$27.50</td>
<td>$29.0K</td>
<td>145</td>
<td>293</td>
</tr>
<tr>
<td>SMMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$20.00</td>
<td>$53.0K</td>
<td>293</td>
<td>246</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$60.00</td>
<td>$76.5K</td>
<td>1.1K</td>
<td>120</td>
</tr>
<tr>
<td>GPCR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$40.00</td>
<td>$121.0K</td>
<td>175</td>
<td>100</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$275.00</td>
<td>$31.5K</td>
<td>590</td>
<td>68</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a put option trade with neutral sentiment. It expires in 2 day(s) on October 18, 2024. Parties traded 2924 contract(s) at a $116.00 strike. The total cost received by the writing party (or parties) was $116.9K, with a price of $40.0 per contract. There were 3761 open contracts at this strike prior to today, and today 3738 contract(s) were bought and sold. 
• Regarding DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we observe a call option sweep with bearish sentiment. It expires in 93 day(s) on January 17, 2025. Parties traded 603 contract(s) at a $100.00 strike. This particular call needed to be split into 81 different trades to become filled. The total cost received by the writing party (or parties) was $66.3K, with a price of $110.0 per contract. There were 2415 open contracts at this strike prior to today, and today 1605 contract(s) were bought and sold. 
• Regarding MOH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), we observe a call option trade with bullish sentiment. It expires in 2 day(s) on October 18, 2024. Parties traded 549 contract(s) at a $330.00 strike. The total cost received by the writing party (or parties) was $156.4K, with a price of $285.0 per contract. There were 55 open contracts at this strike prior to today, and today 720 contract(s) were bought and sold. 
• Regarding CAPR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), we observe a call option trade with bearish sentiment. It expires in 247 day(s) on June 20, 2025. Parties traded 50 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $77.0K, with a price of $1540.0 per contract. There were 3 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold. 
• Regarding EWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), we observe a put option sweep with bearish sentiment. It expires in 2 day(s) on October 18, 2024. Parties traded 300 contract(s) at a $35.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $100.0 per contract. There were 16 open contracts at this strike prior to today, and today 300 contract(s) were bought and sold. 
• Regarding SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on October 25, 2024. Parties traded 100 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $290.0 per contract. There were 145 open contracts at this strike prior to today, and today 293 contract(s) were bought and sold. 
• Regarding SMMT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>), we observe a call option trade with neutral sentiment. It expires in 30 day(s) on November 15, 2024. Parties traded 100 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $53.0K, with a price of $530.0 per contract. There were 293 open contracts at this strike prior to today, and today 246 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 93 day(s) on January 17, 2025. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $76.5K, with a price of $1530.0 per contract. There were 1168 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For GPCR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>), we notice a call option trade that happens to be bullish, expiring in 429 day(s) on December 19, 2025. This event was a transfer of 100 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $121.0K, with a price of $1210.0 per contract. There were 175 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 16 day(s) on November 1, 2024. This event was a transfer of 60 contract(s) at a $275.00 strike. The total cost received by the writing party (or parties) was $31.5K, with a price of $526.0 per contract. There were 590 open contracts at this strike prior to today, and today 68 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXCM

EWTX

GPCR

SAVA

SMMT

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) has outperformed the market over the past 5 years by 32.37% on an annualized basis producing an average annual return of 46.55%. Currently, Capricor Therapeutics has a market capitalization of $616.28 million. 
Buying $1000 In CAPR: If an investor had bought $1000 of CAPR stock 5 years ago, it would be worth $6,785.99 today based on a price of $17.44 for CAPR at the time of writing.
<h3>Capricor Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728677024_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,800 Today

On Friday, Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) announced 3-year safety and efficacy results from its ongoing HOPE-2 open-label extension (OLE) study for its lead asset, deramiocel, for the treatment of Duchenne <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41290995/capricor-therapeutics-announces-positive-long-term-data-from-hope-2-ole-study-in-duchenne-muscular" rel="noreferrer noopener">muscular dystrophy (DMD)</a>.
DMD is&nbsp;a genetic disease that causes progressive muscle weakness and degeneration.&nbsp;
Cardiac and orthopedic complications, including scoliosis and contractures (tightened muscles)&nbsp;
The data was highlighted at the Annual&nbsp;Congress&nbsp;of the&nbsp;World Muscle Society.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40899024/exclusive-capricor-therapeutics-inks-european-expansion-commercialization-pact-for-lead-asset-wit" rel="noreferrer noopener">EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm</a>.
The 3-year data from the HOPE-2 OLE study demonstrated improvements in multiple cardiac function measures, including left ventricular ejection fraction (LVEF%) and indexed volumes, which are considered highly relevant in terms of predicting long-term cardiac outcomes.
In addition, the treatment effect was clearly bifurcated in those with ejection fractions greater than 45% at the end of HOPE-2, suggesting that early and sustained intervention will be key in attenuating the impacts of DMD cardiomyopathy.
To evaluate the relevance of the data to disease progression and the chronic and progressive nature of DMD, where cardiac function can decline year over year, a natural history data set was used to compare the trajectory of those treated with deramiocel to the standard of care.
In addition to the cardiac data, patients demonstrated a statistically and clinically relevant benefit (+3.7 points, p&lt; 0.001) in the PUL v2.0 total score compared to an external comparator dataset of similar DMD patients.
The HOPE-2 OLE study continues to show a favorable safety profile for long-term treatment of deramiocel.
Price Action: CAPR stock is up 8.05% at $18.52 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41290240/fastenal-q3-earnings-revenue-and-eps-beat-sets-cautious-tone-on-2024-outlook" target="_blank" rel="noreferrer noopener">Fastenal Q3 Earnings: Revenue And EPS Beat, Sets Cautious Tone On 2024 Outlook</a>.</li>
</ul>

Biotech

Health Care

General

Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years

U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Friday.
Shares of Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) rose sharply during Friday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41290240/fastenal-q3-earnings-revenue-and-eps-beat-sets-cautious-tone-on-2024-outlook">better-than-expected third-quarter financial results.</a>
Fastenal reported sales growth of 3.5% year-over-year to $1.910 billion, beating the consensus of $1.908 billion. Unit sales increased in the quarter due to growth from larger customers, new Onsite locations, and an extra selling day, despite minor disruptions from Hurricane Helene and stable pricing. The company's third-quarter EPS was 52 cents, above the estimate of 51 cents.
Fastenal shares jumped 6% to $74.18 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) shares jumped 13% to $3.78.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) surged 12% to $1.7350 after the company announced it signed a research collaboration agreement with the National Cancer Center of Singapore. The project will use the company&#8217;s sequencing technologies.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) gained 11.5% to $30.66.</li>
<li>Digital Turbine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) rose 10.6% to $3.2750.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) gained 10.6% to $10.32.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares jumped 10.4% to $18.92 after the company announced it reported long-term data from its HOPE-2 OLE study for Duchenne muscular dystrophy at the 2024 World Muscle Society Congress. Additionally, HC Wainwright &amp; Co. raised its price target on the stock from $40 to $77.</li>
<li>Nuvation Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NASDAQ">NUVB</a>) gained 9.5% to $2.2000.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 9.1% to $10.36.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) gained 8.7% to $13.49 in reaction to Tesla announcing that a rival offering, the Cybercab, will go into production in 2026.</li>
<li>Aehr Test Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) rose 8.6% to $14.47 after the company reported better-than-expected first-quarter financial results.</li>
<li>Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) gained 8.2% to $84.34 in reaction to Tesla announcing that a rival offering, the Cybercab, will go into production in 2026.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) gained 8% to $26.04 on continued upward momentum.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) gained 7.8% to $197.69.</li>
<li>Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) rose 5.6% to $60.98 following upbeat quarterly earnings.</li>
<li>JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) gained 4.6% to $222.57 after reporting strong quarterly results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41270853/jim-cramer-likes-reddit-very-much-calls-accenture-a-great-buy">Jim Cramer Likes Reddit Very Much, Calls Accenture A &#8216;Great Buy&#8217;</a></li>
</ul>

Intraday Update

AEHR

APPS

CURV

FAST

LYFT

MESO

MSTR

NUVB

PACB

UBER

WOLF

Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday

Capricor Therapeutics shares are trading higher after the company announced it reported long-term data from its HOPE-2 OLE study for Duchenne muscular dystrophy at the 2024 World Muscle Society Congress. Additionally, HC Wainwright & Co. raised its price target on the stock from $40 to $77.

-Data Supports Deramiocel's Sustained Efficacy and Safety in Treating DMD- &nbsp;
-Improvements Seen in Multiple Cardiac and Skeletal Endpoints Demonstrating Stabilization of Cardiac and Skeletal Muscle Function Over 3 Years of Treatment-
-Company on Track to Fully Submit Biologics License Application (BLA) by End of 2024-

Capricor Therapeutics Reports Long-Term Data From HOPE-2 OLE Study In Duchenne Muscular Dystrophy At 2024 World Muscle Society Congress

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and raises the price target from $40 to $77.

HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Raises Price Target to $77

Throughout the last three months, 9 analysts have evaluated Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.44, a high estimate of $43.00, and a low estimate of $8.00. This upward trend is apparent, with the current average reflecting a 21.4% increase from the previous average price target of $21.78.
<img src="https://www.benzinga.com/files/images/story/2024/1728500500_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Capricor Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jason McCarthy</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason McCarthy</td>
<td>Maxim Group</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Capricor Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Capricor Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Capricor Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Capricor Therapeutics</h2>
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
<h3>Financial Milestones: Capricor Therapeutics's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Capricor Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.38% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -276.97%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Capricor Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -73.49%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Capricor Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -25.08%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.16.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 9 Analyst Projections For Capricor Therapeutics

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $40 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report), with a...

Buy Rating Affirmed for Capricor Therapeutics Amid Promising Developments in DMD-cardiomyopathy Treatment

Capricor reports positive long-term data for DMD drug deramiocel

Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil

Oppenheimer analyst Leland Gershell maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) today and set a price target of $43.0...

Capricor Therapeutics (CAPR) Receives a Buy from Oppenheimer

Capricor Therapeutics proposes public offering of common stock

Capricor Therapeutics stock falls after pricing $75M equity offering

Capricor Therapeutics ( ($CAPR) ) has shared an update. Capricor Therapeutics has announced a substantial public offering of 4,412,000 shares of co...

Capricor Therapeutics Announces Major Public Offering

Edward Tenthoff, an analyst from Piper Sandler, has initiated a new Buy rating on Capricor Therapeutics (CAPR). Edward Tenthoff's rating is based o...

Buy Rating for Capricor Therapeutics: Promising Deramiocel Development and Strategic Partnerships

Piper Sandler initiated coverage of Capricor Therapeutics (CAPR) with an Overweight rating and $35 price target Capricor is developing deramiocel t...

Capricor Therapeutics initiated with an Overweight at Piper Sandler

17:13 EDT Capricor Therapeutics (CAPR) files to sell 2.8M shares of common stock for holders Published first on TheFly – the ultimate source for re...

Capricor Therapeutics files to sell 2.8M shares of common stock for holders

ADBE

ALLY

BLNK

BYDDF

CPRX

CTRI

CYTK

IBTA

INTC

LNVGY

MIRM

MSCLF

MSFT

MTEN

NAPA

NFLX

NRBO

NVNO

OCGN

OKTA

QCOM

RGNX

RHHBY

SCHW

SERV

SFHG

SLDB

SRPT

SRRK

TRDA

ULTA

USGO

VANI

VLKAF

VRSSF

VRTX

Contracts

Press Releases

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Financing

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

Comments

Capricor Therapeutics

Capricor Therapeutics (CAPR) 옵션

Capricor Therapeutics (NASDAQ:CAPR) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌